Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Cancer Prev Res (Phila). 2011 Sep;4(9):1495-506. doi: 10.1158/1940-6207.CAPR-11-0077. Epub 2011 Jun 16.
The development of prostate cancer and its progression to castrate-resistant prostate cancer (CRPC) after antiandrogen ablation therapy are driven by persistent biological activity of androgen receptor (AR) signaling. Moreover, studies have shown that more than 50% of human prostate cancers overexpress ERG (v-ets avian erythroblastosis virus E26 oncogene related gene) due to AR-regulated TMPRSS2-ERG fusion gene. However, the reported roles of TMPRSS2-ERG fusion in cancer progression are not clear. In this study, we investigated the signal transduction in the AR/TMPRSS2-ERG/Wnt signaling network for studying the aggressive behavior of prostate cancer cells and further assessed the effects of BR-DIM and CDF [natural agents-derived synthetic formulation and analogue of 3,3'-diindolylmethane (DIM) and curcumin, respectively, with improved bioavailability] on the regulation of AR/TMPRSS2-ERG/Wnt signaling. We found that activation of AR resulted in the induction of ERG expression through TMPRSS2-ERG fusion. Moreover, we found that ERG overexpression and nuclear translocation activated the activity of Wnt signaling. Furthermore, forced overexpression of ERG promoted invasive capacity of prostate cancer cells. More important, we found that BR-DIM and CDF inhibited the signal transduction in the AR/TMPRSS2-ERG/Wnt signaling network, leading to the inactivation of Wnt signaling consistent with inhibition of prostate cancer cell invasion. In addition, BR-DIM and CDF inhibited proliferation of prostate cancer cells and induced apoptotic cell death. On the basis of our findings, we conclude that because BR-DIM and CDF downregulate multiple signaling pathways including AR/TMPRSS2-ERG/Wnt signaling, these agents could be useful for designing novel strategies for the prevention and/or treatment of prostate cancer.
前列腺癌的发展及其在抗雄激素消融治疗后进展为去势抵抗性前列腺癌(CRPC)是由雄激素受体(AR)信号的持续生物学活性驱动的。此外,研究表明,由于 AR 调节的 TMPRSS2-ERG 融合基因,超过 50%的人类前列腺癌过表达 ERG(v-ets 禽红细胞白血病病毒 E26 癌基因相关基因)。然而,TMPRSS2-ERG 融合在癌症进展中的报道作用尚不清楚。在这项研究中,我们研究了 AR/TMPRSS2-ERG/Wnt 信号网络中的信号转导,以研究前列腺癌细胞的侵袭行为,并进一步评估 BR-DIM 和 CDF(天然产物衍生的合成制剂和 3,3'-二吲哚甲烷(DIM)和姜黄素的类似物,分别具有改善的生物利用度)对 AR/TMPRSS2-ERG/Wnt 信号的调节作用。我们发现,AR 的激活导致通过 TMPRSS2-ERG 融合诱导 ERG 表达。此外,我们发现 ERG 过表达和核转位激活了 Wnt 信号活性。此外,ERG 的强制过表达促进了前列腺癌细胞的侵袭能力。更重要的是,我们发现 BR-DIM 和 CDF 抑制了 AR/TMPRSS2-ERG/Wnt 信号网络中的信号转导,导致 Wnt 信号失活,与抑制前列腺癌细胞侵袭一致。此外,BR-DIM 和 CDF 抑制前列腺癌细胞的增殖并诱导细胞凋亡。基于我们的发现,我们得出结论,由于 BR-DIM 和 CDF 下调包括 AR/TMPRSS2-ERG/Wnt 信号在内的多个信号通路,这些药物可能有助于设计用于预防和/或治疗前列腺癌的新策略。